Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06353152
Status:
RECRUITING
Last Update Posted:
2024-04-08
First Post:
2023-11-15
Brief Title:
Claudin 182-Targeted Chimeric Antigen Receptor T-cells for GastricGastroesophageal Junction Adenocarcinoma
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
An Early Exploratory Clinical Trial of Claudin182-Targeted Chimeric Antigen Receptor T Cell Therapy for GastricGastroesophageal Junction Adenocarcinoma
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single-arm open-label early-stage exploratory clinical study to evaluate the safety tolerability and efficacy of Claudin 182-Targeted Chimeric Antigen Receptor T-cells in subjects with gastricgastroesophageal junction adenocarcinoma
Detailed Description:
This study is an open-label single-multiple-dose infusion adaptive dose-escalation designed early exploratory clinical trial aiming to evaluate the safety tolerability and efficacy of Claudin182-Targeted Chimeric Antigen Receptor T Cell Injection in subjects with CLDN182 positive and pathologically confirmed locally advanced or metastatic gastricgastroesophageal junction adenocarcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None